{"prompt": "['STABILITY 2', 'Version 1.4', 'PRO19020231', 'February 2, 2021', 'As described in Figure 4, all AEs will be presented to the Pls during the weekly research', 'team meetings unless noted that the AE is also an UP. The AEs will be reviewed', 'internally by the study team at the CCC and DCC on a weekly basis.', 'A summary of AEs will be sent to members of the External Adverse Event Adjudication', 'Committee (EAEAC) every 2 months, with a convened meeting twice annually. A', 'summary of AEs will be included in the biannual report to the DSMB. The site PI will', 'determine the severity of AEs, SAEs and UPs and their relatedness to the study', 'intervention, which will then be confirmed by the EAEAC. The EAEAC will provide an', 'independent, external and systematic review of all participants excluded at the time of', 'surgery as well as all adverse events reported during the conduct of the trial. The', 'EAEAC will independently review the documentation of AEs, SAEs and UPs in terms of', 'their classification, severity and relatedness to study procedures. The members of the', \"EAEAC will be blinded to treatment allocation to ensure the committee's\", 'recommendations are unbiased.', 'The EAEAC will convene for a meeting at least twice annually to discuss the reported', 'events approximately two months prior to the planned DSMB Meetings or as frequently', 'as every 2 months to resolve disagreements Study participants will be identified by a', 'study identification number only in all event reports to ensure participant confidentiality.', 'In addition to the EAEAC, the ESC will monitor AEs in a blinded manner on a monthly', 'basis.', \"The PI will ensure participants' safety by complying with reportable event timelines\", 'described above to the IRB of Record, the NIAMS, and the Data and Safety Monitoring', 'Board (DSMB).', 'The PI will record all reportable events with start dates occurring any time after informed', 'consent is obtained until 7 (for non-serious AEs) or 30 days (for SAEs) after the last day', 'of study participation. At each clinical visit and through the electronic surveys, the', 'research team will actively query participants on the occurrence of any potential health', '71']['STABILITY 2', 'Version 1.4', 'PRO19020231', 'February 2, 2021', 'related event since last contact. Events will be followed for outcome information until', 'resolution or stabilization.', 'All AEs, regardless of their relatedness to the study intervention, will be recorded on the', 'electronic AE form. Hard coded checkboxes will be used when recording and', 'classifying AEs. This standardization will allow sorting and grouping of like events,', 'which will facilitate consistent documentation across all 21 sites as well as the', 'calculation of the incidence of each AE.', 'The data elements that will be recorded on the AE form include event term, event', 'severity (mild, moderate, severe, life-threatening/disabling or death), start and end date,', 'relatedness to study procedures (unrelated, unlikely, possible, probable or definite),', 'action taken with study procedures (none, study procedure interrupted, discontinued or', 'modified), other action taken (none, treatment given, discontinued from study or', 'hospitalization), event status (recovered/resolved resolved with sequelae,', 'recovering/resolving, not recovered/resolved, fatal, unknown or lost to follow-up), and', 'whether the event was an SAE.', 'Figure 4. Flow Chart of Internal and External Adjudication of AEs', 'Canadian', 'Sites AEs', 'EmPower', 'U.S', 'Health', 'Internal', 'AE', 'Data & Safety', 'Sites AEs', 'Research', 'Adjudication', 'Adjudication', 'Monitoring', '(DCC)', 'Review', 'Committee', 'Board', 'European', 'Every 2 weeks', 'Every 2 months', 'Biannually', 'Sites AEs', '*', 'The Steering Committee will monitor AEs and SAEs on a monthly basis', '72']['STABILITY 2', 'Version 1.4', 'PRO19020231', 'February 2, 2021', '11 ETHICS/PROTECTION OF HUMAN SUBJECTS', '11.1', 'Ethical Standard', 'The Principal Investigators will ensure that this study is conducted in full conformity with', 'the principles set forth in The Belmont Report: Ethical Principles and Guidelines for the', 'Protection of Human Subjects of Research, as drafted by the US National Commission', 'for the Protection of Human Subjects of Biomedical and Behavioral Research (April 18,', \"1979) and codified in 45 CFR Part 46 and/or the ICH E6 or another country's ethical\", 'policy statement, whichever provides the most protection to human subjects.', '11.2', 'Institutional/Ethics Review Board', 'The University of Pittsburgh Institutional Review Board (IRB) will serve as the IRB of', 'Record for all clinical research sites in the US. To facilitate prompt IRB review and', 'approval, the University of Pittsburgh will utilize the SMART IRB process to establish', 'the reliance agreement with the other US clinical research sites. A similar process will', 'take place for the Canadian sites, as sites under the same province will be submitted', 'with one regulatory ethics board serving as the regulatory board of record (i.e. Clinical', 'Trials Ontario will serve as the regulatory ethics board whose approval applies to any', 'site located in Ontario, Canada). For the Canadian sites outside of Ontario, the study', 'protocol will be submitted to local ethics review board/institution for review and', 'approval, as per their institutional requirements, prior to initiation of any study', 'procedures.', 'For the European sites, the study protocol will be submitted to local ethics review', 'board/institution for review and approval, as per their institutional requirements, prior to', 'initiation of any study procedures.', '11.3', 'Informed Consent Process', 'For sites using traditional randomization, surgeons will describe the study to eligible', 'patients including foreseeable risks. If interested, the CRA will provide the patient with', 'the IRB approved consent form, further describe the study, including that randomization', '73']\n\n###\n\n", "completion": "END"}